Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 12/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16008825 | 1.00 | FFAR1 (0.40) | FFAR1LPLLIPGHIF1ADGAT1 | |
| SCHEMBL22185786 | 0.89 | LPL (0.40) | FFAR1LPLLIPGHIF1ADGAT1 | |
| SCHEMBL23597018 | 0.87 | FFAR1 (0.44) | FFAR1LPLLIPGHIF1ADGAT1 | |
| SCHEMBL406138 | 0.85 | AR (0.40) | FFAR1LPLLIPG | |
| SCHEMBL29506948 | 0.85 | AR (0.40) | FFAR1LPLLIPG | |
| SCHEMBL24023348 | 0.84 | LPL (0.37) | FFAR1LPLLIPGHIF1ADGAT1 | |
| SCHEMBL22977685 | 0.84 | DGAT1 (0.38) | FFAR1LPLLIPGHIF1ADGAT1 | |
| SCHEMBL19876295 | 0.84 | ALDH1A1 (0.37) | FFAR1LPLLIPG | |
| SCHEMBL22289520 | 0.83 | FFAR1 (0.42) | FFAR1LPLLIPGHIF1ADGAT1 | |
| SCHEMBL12989288 | 0.83 | FFAR1 (0.36) | FFAR1LPLLIPGHIF1ADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | SREBF1, SREBF2, XBP1 | FFAR1 810/4885LPL 450/4885LIPG 995/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | FFAR1 1395/4885LPL 1442/4885LIPG 1293/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | FFAR1 950/4885LPL 1381/4885LIPG 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.